为探讨乳腺癌Ｐ６２Ｃｍｙｃ蛋白表达与雌激素和孕激素受体的关系及其临床意义，采用ＬＳＡＢ免疫组化法对１０７例乳腺癌标本进行Ｐ６２Ｃｍｙｃ蛋白检测。结果：Ｐ６２Ｃｍｙｃ蛋白表达阳性率为６３．５５％（６８／１０７），在生存时间≤５年、＞５年＜１０年及≥１０年者，其Ｐ６２Ｃｍｙｃ蛋白表达阳性率分别为９４．００％（４７／５０），６５．００％（１３／２０）和２１．６２％（８／３７），表明Ｐ６２Ｃｍｙｃ蛋白过度表达与乳腺癌的临床分期晚、组织学分级高及腋淋巴结转移有关，而与雌、孕激素受体状况关系不大。由此提示：Ｐ６２Ｃｍｙｃ蛋白表达可作为判断乳腺癌预后的一个重要指标。 To explore the relationship between the expression of P62Cmyc protein and estrogen and progesterone receptors in breast cancer, LSAB immunohistochemistry was used to detect P62Cmyc protein in 107 breast cancer specimens. RESULTS: The positive rate of P62Cmyc protein expression was 63.55% (68/107). The positive rate of P62Cmyc protein expression in the patients with survival time ≤5 years, >5 years<10 years and ≥10 years was 94 respectively. .00% (47/50), 65.00% (13/20), and 21.62% (8/37), indicating that P62Cmyc overexpression is associated with late clinical staging, high histological grade, and delirium Lymph node metastasis is related to the status of estrogen and progesterone receptors. This suggests that the expression of P62Cmyc protein can be used as an important indicator to determine the prognosis of breast cancer.